Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Panayiotis Panayiotidis, Gayane Tumyan, Catherine Thieblemont, Vadim V. Ptushkin, Ana Marin-Niebla, Ramon García-Sanz, Steven Le Gouill, Anastasios Stathis, Alessia Bottos, Habib Hamidi, Pablo Katz, Thomas Perretti, Jenna C. Willis & Christian Buske. (2022) A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia. Leukemia & Lymphoma 63:5, pages 1058-1069.
Read now
Read now
Nina D. Wagner-Johnston, Stephen J. Schuster, Sven deVos, Gilles Salles, Wojciech J. Jurczak, Christopher R. Flowers, Andreas Viardot, Ian W. Flinn, Peter Martin, Guan Xing, Nishanthan Rajakumaraswamy & Ajay K. Gopal. (2021) Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. Leukemia & Lymphoma 62:5, pages 1077-1087.
Read now
Read now
Articles from other publishers (21)
Alexandre Guérémy, José Boucraut, John Boudjarane, Aude-Marie Grapperon, Etienne Fortanier, Laure Farnault, Jean Gabert, Frédéric Vely, Romaric Lacroix, Ludivine Kouton, Shahram Attarian & Emilien Delmont. (2023) Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88L265P and CXCR4 mutations and underlying haemopathy. Journal of Neurology 271:3, pages 1320-1330.
Crossref
Crossref
Renata Walewska, Toby A. Eyre, Sally Barrington, Jessica Brady, Paul Fields, Sunil Iyengar, Anurag Joshi, Tobias Menne, Nilima Parry‐Jones, Harriet Walter, Andrew Wotherspoon & Kim Linton. (2023) Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline. British Journal of Haematology 204:1, pages 86-107.
Crossref
Crossref
Stephen Opat, Alessandra Tedeschi, Bei Hu, Kim M. Linton, Pamela McKay, Sophie Leitch, Morton Coleman, Pier Luigi Zinzani, Jie Jin, Mingyuan Sun, Magdalena Sobieraj-Teague, Peter Browett, Xiaoyan Ke, Catherine Thieblemont, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza A. Hawkes, Shir-Jing Ho, Keshu Zhou, Zhiyu Liang, Jianfeng Xu, Chris Tankersley, Richard Delarue, Melannie Co & Judith Trotman. (2023) Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study. Blood Advances 7:22, pages 6801-6811.
Crossref
Crossref
William Townsend, Wolfgang Hiddemann, Christian Buske, Guillaume Cartron, David Cunningham, Martin J.S. Dyer, John G. Gribben, Elizabeth H. Phillips, Martin Dreyling, John F. Seymour, Andrew Grigg, Judith Trotman, Tong-Yu Lin, Xiao-Nan Hong, Dirk Kingbiel, Tina G. Nielsen, Andrea Knapp, Michael Herold & Robert Marcus. (2023) Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. HemaSphere 7:7, pages e919.
Crossref
Crossref
John Kuruvilla, Emmanuel M. Ewara, Julia Elia-Pacitti, Ryan Ng, Maria Eberg, Atif Kukaswadia & Arushi Sharma. (2023) Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada. Current Oncology 30:5, pages 4663-4676.
Crossref
Crossref
Montserrat Miret, Amanda Anderson, Pooja Hindocha, Lorena Cirneanu, Christina Lymperopoulou, Emanuil Markov, William Kizito & Ferdinando Emanuele Vegni. (2023) Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin’s lymphoma patients in England. Leukemia Research 127, pages 107042.
Crossref
Crossref
Abdalrahim M. Ali, Alaa A. Makki, Walaa Ibraheem, Mohammed Abdelrahman, Wadah Osman, Asmaa E. Sherif, Ahmed Ashour, Sabrin R. M. Ibrahim, Kholoud F. Ghazawi, Waad A. Samman & Abdulrahim A. Alzain. (2023) Design of Novel Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin’s Lymphoma: Molecular Docking, Molecular Dynamics, and Density Functional Theory Studies on Gold Nanoparticles. Molecules 28:5, pages 2289.
Crossref
Crossref
Shao-Liang Jiang, Li Li, Lu Hu, Song-Bo Kou & Jie-Hua Shi. (2023) Comprehending binding features between ibrutinib and Human Alpha-1 acid glycoprotein: Combined experimental approaches and theoretical simulations. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 285, pages 121834.
Crossref
Crossref
Ping Song, Yuan Tian, Guizhou Hao, Lisa Xu, Yan Sun & Yong Sun. (2022) Preparation and evaluation of ibrutinib lipid-based formulations. Journal of Drug Delivery Science and Technology 77, pages 103912.
Crossref
Crossref
Tycel Phillips, Henry Chan, Constantine S. Tam, Alessandra Tedeschi, Patrick Johnston, Sung Yong Oh, Stephen Opat, Hyeon-Seok Eom, Heather Allewelt, Jennifer C. Stern, Ziwen Tan, William Novotny, Jane Huang & Judith Trotman. (2022) Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Advances 6:11, pages 3472-3479.
Crossref
Crossref
Yaqin Xia, Jurui Ge, Zhenchang Sun, Feifei Nan, Wenjuan Wan, Duo Xu, Mingzhi Zhang & Xiaorui Fu. (2022) CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes. Leukemia Research 117, pages 106840.
Crossref
Crossref
Michael Herold, Eva Hoster, Ann Janssens, Helen McCarthy, Alessandra Tedeschi, Chris Pocock, Andras Rosta, Marek Trněný, Tina G. Nielsen, Andrea Knapp, Wolfgang Hiddemann & Robert Marcus. (2022) Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial. HemaSphere 6:3, pages e699.
Crossref
Crossref
Sung-Hsin Kuo, Kun-Huei Yeh, Chung-Wu Lin, Jyh-Ming Liou, Ming-Shiang Wu, Li-Tzong Chen & Ann-Lii Cheng. (2022) Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers 14:4, pages 1005.
Crossref
Crossref
Stephen Opat, Alessandra Tedeschi, Kim Linton, Pamela McKay, Bei Hu, Henry Chan, Jie Jin, Magdalena Sobieraj-Teague, Pier Luigi Zinzani, Morton Coleman, Catherine Thieblemont, Peter Browett, Xiaoyan Ke, Mingyuan Sun, Robert Marcus, Craig A. Portell, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza A. Hawkes, Sally Mapp, Shir-Jing Ho, Dipti Talaulikar, Ke-Shu Zhou, Melannie Co, Xiaotong Li, Wenxiao Zhou, Massimo Cappellini, Chris Tankersley, Jane Huang & Judith Trotman. (2021) The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clinical Cancer Research 27:23, pages 6323-6332.
Crossref
Crossref
Wolfgang Knauf, Wolfgang Abenhardt, Michael Koenigsmann, Christoph Maintz, Reiner Sandner, Mark‐Oliver Zahn, Roland Schnell, Susanne Tech, Anja Kaiser‐Osterhues, Leonora Houet & Norbert Marschner. (2021) Rare lymphomas in routine practice – Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms. Hematological Oncology 39:3, pages 313-325.
Crossref
Crossref
Matthew R. Fleming, Ling Xiao, Klarissa D. Jackson, Joshua A. Beckman, Ana BaracJavid J. Moslehi. (2021) Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. Circulation Research 128:12, pages 1973-1987.
Crossref
Crossref
Nathan H. Fowler, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A. Reeves, Wanda Knopińska-Posłuszny, Chan Y. Cheah, Tycel Phillips, Ewa Lech-Maranda, Bruce D. Cheson, Paolo F. Caimi, Sebastian Grosicki, Lori A. Leslie, Julio C. Chavez, Gustavo Fonseca, Sunil Babu, Daniel J. Hodson, Spencer H. Shao, John M. Burke, Jeff P. Sharman, Jennie Y. Law, John M. Pagel, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Michael S. Weiss & Pier Luigi Zinzani. (2021) Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. Journal of Clinical Oncology 39:15, pages 1609-1618.
Crossref
Crossref
Amy L. Whillock, Tiffany K. Ybarra & Gail A. Bishop. (2021) TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells. Journal of Biological Chemistry 296, pages 100465.
Crossref
Crossref
Mesut Göçer & Erdal Kurtoğlu. (2020) Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey. BLOOD RESEARCH 55:4, pages 206-212.
Crossref
Crossref
Ariela Noy, Sven de VosMorton Coleman, Peter MartinChristopher R. FlowersCatherine ThieblemontFranck Morschhauser, Graham P. CollinsShuo MaShachar PelesStephen D. Smith, Jacqueline C. BarrientosElizabeth Chong, Shiquan Wu, Leo W.-K. Cheung, Kevin Kwei, Bernhard Hauns, Israel Arango-Hisijara & Robert Chen. (2020) Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Advances 4:22, pages 5773-5784.
Crossref
Crossref
Lidia Felicia Mihai. (2020) Nodal marginal zone lymphoma – etiopathology, diagnosis and treatment. Oncolog-Hematolog.ro 1:50, pages 47.
Crossref
Crossref